Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Biophytis ( (BPTSY) ).
On September 11, 2025, Biophytis SA announced its Phase 3 trial strategy for BIO101, targeting sarcopenia in Europe and Asia. This trial aims to recruit 932 patients, primarily from China, Japan, and Europe, reflecting the significant medical need and commercial potential in these rapidly aging regions. With no approved drugs currently available for sarcopenia, BIO101 has the potential to become a foundational therapy in this growing market. Biophytis plans to finance the trial through collaborations with regional pharmaceutical companies and local investors, aiming to maximize co-commercialization rights and reduce development costs. The company is advancing towards trial initiation, with regulatory processes underway in Europe, China, and Japan, and expects to generate multiple value catalysts as it strengthens its pipeline and market presence.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is in development for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is listed on Euronext Growth Paris and the OTC market.
Technical Sentiment Signal: Sell
Current Market Cap: $4.59M
Learn more about BPTSY stock on TipRanks’ Stock Analysis page.